# Evommune, Inc. (EVMN)

> Evommune, Inc. (EVMN) trades at $6.88 (-1.99%) as of 7:13:04 PM EST on Nov 18, 2026, +27.88% over the past month. Market cap is $290.28M, with 3.0 days to cover in short interest.

Canonical: https://massive.com/quote/evmn
Data as of: 2026-11-19T00:13:04.447Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$6.88** -0.14 (-1.99%)
At close · 15-minute delayed
NYSE · usd

After hours: **$7.08** +0.20 (+2.91%)
As of 7:13:04 PM EST on Nov 18, 2026 · After hours

## Stock performance

How Evommune, Inc. (EVMN) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -1.99% |
| 1W | -20.19% |
| 1M | +27.88% |
| YTD | -59.81% |
| 1Y | -64.33% |
| 52-wk range | $4.94 – $33.20 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for EVMN: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $6.74 – $7.22 |
| Open | $6.89 |
| Prev close | $7.02 |
| Volume | 600.36K |
| Market cap | $290.28M |
| Shares out | 41.35M |

## Valuation and profitability ratios

Valuation and profitability ratios for Evommune, Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 1.15 |
| P/FCF | — |
| ROE | -45.0% |
| ROA | -40.6% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 17, 2026

## Insider trading

[Evommune, Inc. (EVMN) insider trading](https://massive.com/quote/evmn/insider-trading.md): open-market Form 4 buys and sells by Evommune, Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events Evommune, Inc. has disclosed to the SEC on Form 8-K.

- Nov 17, 2026 · Executive compensation change
  “On November 13, 2026, the Compensation Committee ... approved the entry of an amendment to the applicable employment agreement(s) ... with certain executive officers of the Company, including the Chief Executive Officer, the Chief Financial Officer, and the Chief Business & Legal Officer, pursuant to which ... such officer will be eligible to earn a cash retention award.”
- Nov 12, 2026 · Investor presentation
  “On November 12, 2026, the Company updated its corporate presentation to reflect certain business updates. The presentation is available in the "Investors & Media" section of the Company's website at ir.evommune.com, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.”
- Nov 5, 2026 · Investor presentation
  “On November 5, 2026, the Company issued a press release announcing a live webcast on EVO570. The Company will make available a copy of the presentation from the webcast on the News & Events page of the Company's website at https://ir.evommune.com/news-events/ir-calendar.”
- Nov 4, 2026 · Underwriting agreement
  “Morgan Stanley & Co. LLC and Leerink Partners LLC acted as placement agents for the Private Placement ... The Company has agreed to pay the placement agents customary placement fees in their capacity as placement agents for the sale of the Shares to the Investors.”
- Sep 15, 2026 · Investor presentation
  “On September 15, 2026, Evommune, Inc. (the "Company") posted an updated corporate presentation on the "Company Info" page of the Company's website at https://ir.evommune.com/company-info/presentations. A copy of the presentation is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.”

## EVMN short interest

How heavily EVMN is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 3.0 |
| Short interest | 3.39M |
| Avg volume | 1.15M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## EVMN news

The latest news and headlines about Evommune, Inc. (EVMN).

- [Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates](https://www.zacks.com/stock/news/3028407/pelthos-therapeutics-inc-pths-reports-q3-loss-lags-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3028407) · Zacks Investment Research · Nov 12, 2026 · negative sentiment
- [Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches \| DelveInsight](https://www.globenewswire.com/news-release/2026/10/19/3383774/0/en/migraine-market-is-expected-to-expand-at-6-growth-rate-by-2036-owing-to-the-development-of-novel-mechanisms-beyond-cgrp-including-pacap-targeted-therapies-trpa1-antagonists-and-nex.html) · GlobeNewswire Inc. · Oct 19, 2026 · positive sentiment

## About Evommune, Inc.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

| Measure | Value |
| --- | --- |
| Exchange | NYSE |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 48 |
| Listed | Nov 6, 2025 |

[Company website](https://www.evommune.com)

## FAQ

### What is the Evommune, Inc. (EVMN) stock price today?

Evommune, Inc. (EVMN) is trading at $6.88 (-1.99% on the day) as of 7:13:04 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Evommune, Inc.?

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative…

### What is the short interest in EVMN?

As of Oct 30, 2026, EVMN has 3.39M shares short and 3.0 days to cover.

### What exchange is EVMN listed on?

Evommune, Inc. (EVMN) trades on NYSE in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time EVMN quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=EVMN`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Evommune, Inc. (EVMN) insider trading](https://massive.com/quote/evmn/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
